Effect of ribavirin therapy on respiratory syncytial virus-specific IgE and IgA responses after infection.
D000914:Antibodies, Viral / Q000096:biosynthesis; D006801:Humans; D007071:Immunoglobulin A, Secretory / Q000096:biosynthesis; D007073:Immunoglobulin E / Q000096:biosynthesis*; D007223:Infant; D009305:Nasopharynx / Q000378:metabolism; D012136:Respiratory Syncytial Viruses / Q000276:immunology*; D012141:Respiratory Tract Infections / Q000188:drug therapy / Q000276:immunology*; D010253:Respirovirus Infections / Q000188:drug therapy / Q000276:immunology*; D012254:Ribavirin / Q000627:therapeutic use*; D012263:Ribonucleosides / Q000627:therapeutic use*
D000914:Antibodies, Viral; D007071:Immunoglobulin A, Secretory; D012263:Ribonucleosides; D007073:Immunoglobulin E; D012254:Ribavirin